An individual business portfolio restructuring transaction involving the transfer of Mitsubishi Tanabe Pharma Corporation and its subsidiaries to an investment fund under Bain Capital through an absorption-type company split, followed by their removal from the group of subsidiaries. The aim is to operate the business under the best owner to drive renewed growth in the Pharma business.